{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:30:26Z","timestamp":1776353426017,"version":"3.51.2"},"reference-count":194,"publisher":"Elsevier BV","issue":"3-4","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Vascular Surgery"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1053\/j.semvascsurg.2015.04.003","type":"journal-article","created":{"date-parts":[[2015,4,7]],"date-time":"2015-04-07T15:40:05Z","timestamp":1428421205000},"page":"182-195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Fibrinogen and catheter-directed thrombolysis"],"prefix":"10.1053","volume":"27","author":[{"given":"Reagan L.","family":"Ross","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam W.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.semvascsurg.2015.04.003_bib1","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1365-2141.1972.tb05715.x","article-title":"Metabolism and distribution of fibrinogen. I. Fibrinogen turnover in physiological conditions in humans","volume":"22","author":"Collen","year":"1972","journal-title":"Br J Haematol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib2","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/scientificamerican1281-126","article-title":"Fibrinogen and fibrin","volume":"245","author":"Doolittle","year":"1981","journal-title":"Sci Am"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0037-1615130","article-title":"A three-dimensional consideration of variant human fibrinogens","volume":"80","author":"Everse","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1055\/s-2007-994933","article-title":"Dysfibrinogenemia and thrombosis","volume":"25","author":"Mosesson","year":"1999","journal-title":"Semin Thromb Hemost"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib5","first-page":"177","article-title":"The roles of fibrinogen and fibrin in hemostasis and thrombosis","volume":"29","author":"Mosesson","year":"1992","journal-title":"Semin Hematol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib6","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0950-3536(89)80053-8","article-title":"Control of plasma fibrinogen levels","volume":"2","author":"Green","year":"1989","journal-title":"Baillieres Clin Haematol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib7","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1053\/euhj.1999.2207","article-title":"Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6","volume":"21","author":"Woods","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib8","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/0735-1097(93)90213-K","article-title":"Myocardial injury: the acute phase response and lipoprotein metabolism","volume":"22","author":"Rosenson","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib9","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1054\/mehy.1997.0684","article-title":"Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline","volume":"52","author":"McCarty","year":"1999","journal-title":"Med Hypotheses"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1050-1738(01)00157-8","article-title":"Interactions of intercellular adhesion molecule-1 with fibrinogen","volume":"12","author":"Tsakadze","year":"2002","journal-title":"Trends Cardiovasc Med"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib11","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1161\/01.ATV.18.12.1948","article-title":"Adsorption of fibrinogen to droplets of liquid hydrophobic phases. Functionality of the bound protein and biological implications","volume":"18","author":"Retzinger","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib12","doi-asserted-by":"crossref","first-page":"12591","DOI":"10.1073\/pnas.95.21.12591","article-title":"Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice","volume":"95","author":"Lou","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0021-9150(01)00503-2","article-title":"Variability in fibrinogen measurements: an obstacle to cardiovascular risk stratification","volume":"159","author":"Rosenson","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib14","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0140-6736(87)92557-8","article-title":"Genetic and cultural inheritance of plasma fibrinogen concentration","volume":"2","author":"Hamsten","year":"1987","journal-title":"Lancet"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib15","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/S0140-6736(87)92205-7","article-title":"Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations","volume":"1","author":"Humphries","year":"1987","journal-title":"Lancet"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib16","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1161\/01.ATV.18.10.1559","article-title":"Segregation analysis of plasminogen activator inhibitor-1 and fibrinogen levels in the NHLBI family heart study","volume":"18","author":"Pankow","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib17","doi-asserted-by":"crossref","first-page":"10574","DOI":"10.1016\/S0021-9258(18)91001-X","article-title":"Fibrinogen precursors. Order of assembly of fibrinogen chains","volume":"259","author":"Yu","year":"1984","journal-title":"J Biol Chem"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib18","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/0140-6736(92)93009-C","article-title":"Serum cholesterol, triglycerides, and aggression in the general population","volume":"340","author":"Fowkes","year":"1992","journal-title":"Lancet"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib19","first-page":"440","article-title":"Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study","volume":"93","author":"Behague","year":"1996","journal-title":"Etude Cas-Temoins sur l\u05f3Infarctus du Myocarde. Circulation"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib20","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1399-0004.1996.tb02623.x","article-title":"Association of genetic variation at the beta-fibrinogen gene locus and plasma fibrinogen levels; interaction between allele frequency of the G\/A-455 polymorphism, age and smoking","volume":"50","author":"Thomas","year":"1996","journal-title":"Clin Genet"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib21","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1161\/01.ATV.17.12.3489","article-title":"Bcl I polymorphism in the fibrinogen beta-chain gene is associated with the risk of familial myocardial infarction by increasing plasma fibrinogen levels. A case-control study in a sample of GISSI-2 patients","volume":"17","author":"Zito","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1055\/s-0037-1614622","article-title":"Helicobacter pylori infection and the risk of myocardial infarction: role of fibrinogen and its genetic control","volume":"82","author":"Zito","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/humu.1380030117","article-title":"Linkage disequilibrium across the fibrinogen locus as shown by five genetic polymorphisms, G\/A-455 (HaeIII), C\/T-148 (HindIII\/AluI), T\/G+1689 (AvaII), and BclI (beta-fibrinogen) and TaqI (alpha-fibrinogen), and their detection by PCR","volume":"3","author":"Thomas","year":"1994","journal-title":"Hum Mutat"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib24","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1161\/01.ATV.15.7.856","article-title":"Gender-related association between beta-fibrinogen genotype and plasma fibrinogen levels and linkage disequilibrium at the fibrinogen locus in Greenland Inuit","volume":"15","author":"de Maat","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib25","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1055\/s-0038-1649699","article-title":"The role of beta-fibrinogen genotype in determining plasma fibrinogen levels in young survivors of myocardial infarction and healthy controls from Sweden","volume":"70","author":"Green","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib26","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/01.ATV.15.1.96","volume":"15","author":"Humphries","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib27","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1172\/JCI119499","article-title":"A common mutation (G-455--> A) in the beta-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on the Copenhagen City Heart Study","volume":"99","author":"Tybjaerg-Hansen","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib28","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1055\/s-0038-1656123","article-title":"Positive association of the beta fibrinogen H1\/H2 gene variation to basal fibrinogen levels and to the increase in fibrinogen concentration during acute phase reaction but not to coronary artery disease and myocardial infarction","volume":"77","author":"Gardemann","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib29","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.ATV.17.2.246","article-title":"Polymorphisms of factor V, factor VII, and fibrinogen genes. Relevance to severity of coronary artery disease","volume":"17","author":"Wang","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib30","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1055\/s-0038-1642511","article-title":"Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms\u2014the Leiden Thrombophilia Study (LETS)","volume":"71","author":"Koster","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib31","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.2337\/diacare.19.11.1265","article-title":"Beta-fibrinogen gene-455 G\/A polymorphism and fibrinogen levels. Risk factors for coronary artery disease in subjects with NIDDM","volume":"19","author":"Carter","year":"1996","journal-title":"Diabetes Care"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib32","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1161\/01.ATV.16.3.386","article-title":"The acute rise in plasma fibrinogen concentration with exercise is influenced by the G-453-A polymorphism of the beta-fibrinogen gene","volume":"16","author":"Montgomery","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib33","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/jmg.34.7.553","article-title":"The effects of genotype and infant weight on adult plasma levels of fibrinogen, factor VII, and LDL cholesterol are additive","volume":"34","author":"Henry","year":"1997","journal-title":"J Med Genet"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib34","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1055\/s-0038-1653824","article-title":"Raised plasma fibrinogen concentrations in subjects attending a metabolic ward\u2014relation to family history and vascular risk factors","volume":"73","author":"Margaglione","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib35","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0049-3848(95)91608-N","article-title":"Impact of polymorphisms in the alpha- and beta-fibrinogen gene on plasma fibrinogen concentrations of coronary heart disease patients","volume":"77","author":"Heinrich","year":"1995","journal-title":"Thromb Res"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib36","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1055\/s-0037-1615362","article-title":"Fibrinogen plasma levels in an apparently healthy general population\u2014relation to environmental and genetic determinants","volume":"80","author":"Margaglione","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib37","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1055\/s-0037-1614523","article-title":"Fibrinogen, factor VII and PAI-1 genotypes and the risk of coronary and peripheral atherosclerosis: Edinburgh Artery Study","volume":"81","author":"Lee","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib38","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1046\/j.1365-2141.2000.02266.x","article-title":"Fibrinogen polymorphisms are not associated with the risk of myocardial infarction","volume":"110","author":"Doggen","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib39","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1161\/01.ATV.19.12.3063","article-title":"Two common, functional polymorphisms in the promoter region of the beta-fibrinogen gene contribute to regulation of plasma fibrinogen concentration","volume":"19","author":"van \u05f3t Hooft","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib40","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1007\/s001250051300","article-title":"Beta-fibrinogen gene G\/A-455 polymorphism in relation to fibrinogen concentrations and ischaemic heart disease in Chinese patients with type II diabetes","volume":"42","author":"Lam","year":"1999","journal-title":"Diabetologia"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib41","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1161\/01.ATV.17.11.2880","article-title":"The apolipoprotein E and beta-fibrinogen G\/A-455 gene polymorphisms are associated with ischemic stroke involving large-vessel disease","volume":"17","author":"Kessler","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib42","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1055\/s-0038-1656072","article-title":"Variation in plasma fibrinogen over one year: relationships with genetic polymorphisms and non-genetic factors","volume":"77","author":"Vaisanen","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib43","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S1047-2797(00)00203-9","article-title":"Beta-fibrinogen gene -455G\/A polymorphism and coronary heart disease incidence: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"11","author":"Folsom","year":"2001","journal-title":"Ann Epidemiol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib44","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/aje\/153.8.799","article-title":"Ethnic differences in fibrinogen levels: the role of environmental factors and the beta-fibrinogen gene","volume":"153","author":"Cook","year":"2001","journal-title":"Am J Epidemiol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib45","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/00005768-199609000-00013","article-title":"Physical activity, fitness, and plasma fibrinogen with reference to fibrinogen genotypes","volume":"28","author":"Vaisanen","year":"1996","journal-title":"Med Sci Sports Exerc"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib46","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1055\/s-0037-1616079","article-title":"A novel transgenic mouse model of hyperfibrinogenemia","volume":"86","author":"Gulledge","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib47","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib48","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa021993","article-title":"Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events","volume":"347","author":"Ridker","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib49","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1161\/01.CIR.0000120707.98922.E3","article-title":"C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany","volume":"109","author":"Koenig","year":"2004","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib50","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa040967","article-title":"Inflammatory markers and the risk of coronary heart disease in men and women","volume":"351","author":"Pai","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib51","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/01.CIR.0000116763.91992.F1","article-title":"Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study","volume":"109","author":"Ballantyne","year":"2004","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib52","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1056\/NEJMoa032804","article-title":"C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease","volume":"350","author":"Danesh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib53","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.104.489260","article-title":"C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study","volume":"112","author":"Best","year":"2005","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib54","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/eurheartj\/ehi237","article-title":"C-reactive protein in the prediction of cardiovascular and overall mortality in middle-aged men: a population-based cohort study","volume":"26","author":"Laaksonen","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib55","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.atherosclerosis.2005.09.023","article-title":"C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003","volume":"187","author":"Boekholdt","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib56","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/eurheartj\/ehn049","article-title":"Biomarkers of inflammation predict both vascular and non-vascular mortality in older men","volume":"29","author":"Clarke","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib57","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJM198408233110804","article-title":"Fibrinogen as a risk factor for stroke and myocardial infarction","volume":"311","author":"Wilhelmsen","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib58","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1001\/jama.1987.03400090067035","article-title":"Fibrinogen and risk of cardiovascular disease. The Framingham Study","volume":"258","author":"Kannel","year":"1987","journal-title":"JAMA"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib59","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0735-1097(99)00007-8","article-title":"A prospective study of fibrinogen and risk of myocardial infarction in the Physicians\u05f3 Health Study","volume":"33","author":"Ma","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib60","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.105.601641","article-title":"Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy","volume":"114","author":"Maki-Petaja","year":"2006","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib61","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1161\/CIRCULATIONAHA.105.535435","article-title":"Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals","volume":"112","author":"Vlachopoulos","year":"2005","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib62","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1046\/j.1523-1755.63.s84.25.x","article-title":"Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients","volume":"84","author":"London","year":"2003","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib63","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.atherosclerosis.2004.04.014","article-title":"C-reactive protein and arterial stiffness in older adults: the Rotterdam Study","volume":"176","author":"Mattace-Raso","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib64","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1161\/01.HYP.0000185463.27209.b0","article-title":"Arterial stiffness is related to systemic inflammation in essential hypertension","volume":"46","author":"Mahmud","year":"2005","journal-title":"Hypertension"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib65","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/sj.jhh.1001860","article-title":"Relationship between C-reactive protein and arterial stiffness in an asymptomatic population","volume":"19","author":"Duprez","year":"2005","journal-title":"J Hum Hypertens"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib66","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/01.ATV.zhq0504.0173","article-title":"C-reactive protein is associated with arterial stiffness in apparently healthy individuals","volume":"24","author":"Yasmin","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib67","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1161\/01.HYP.38.3.399","article-title":"Blood pressure and inflammation in apparently healthy men","volume":"38","author":"Chae","year":"2001","journal-title":"Hypertension"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib68","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1161\/CIRCULATIONAHA.104.483628","article-title":"Health ABC Study. Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults","volume":"111","author":"Sutton-Tyrrell","year":"2005","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib69","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1161\/01.CIR.101.7.744","article-title":"Hyperfibrinogenemia is associated with specific histocytological composition and complications of atherosclerotic carotid plaques in patients affected by transient ischemic attacks","volume":"101","author":"Mauriello","year":"2000","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib70","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1055\/s-0037-1613597","article-title":"Oxysterols suppress constitutive fibrinogen expression","volume":"90","author":"Xia","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib71","doi-asserted-by":"crossref","first-page":"956","DOI":"10.7326\/0003-4819-118-12-199306150-00008","article-title":"Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature","volume":"118","author":"Ernst","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib72","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1161\/01.ATV.19.6.1368","article-title":"Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update","volume":"19","author":"Maresca","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib73","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1001\/jama.279.18.1477","article-title":"Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies","volume":"279","author":"Danesh","year":"1998","journal-title":"JAMA"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib74","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1001\/jama.285.19.2481","article-title":"Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease","volume":"285","author":"Ridker","year":"2001","journal-title":"JAMA"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib75","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa1107477","article-title":"C-reactive protein, fibrinogen, and cardiovascular disease prediction","volume":"367","author":"Kaptoge","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib76","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1161\/01.CIR.92.1.31","article-title":"Fibrinogen after coronary angioplasty as a risk factor for restenosis","volume":"92","author":"Montalescot","year":"1995","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib77","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1055\/s-0037-1613118","article-title":"Fibrinogen predicts restenosis after endovascular treatment of the iliac arteries","volume":"87","author":"Schillinger","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib78","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0002-9343(01)00914-7","article-title":"A prospective study of plasma fibrinogen levels and the risk of stroke among participants in the bezafibrate infarction prevention study","volume":"111","author":"Tanne","year":"2001","journal-title":"Am J Med"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib79","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1055\/s-0037-1613020","article-title":"Fibrinogen, viscosity and white blood cell count predict myocardial, but not cerebral infarction: evidence from the Caerphilly and Speedwell cohort","volume":"87","author":"Baker","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib80","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1161\/01.CIR.100.7.736","article-title":"Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators","volume":"100","author":"Folsom","year":"1999","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib81","article-title":"Prediction of stroke in the general population in Europe (EUROSTROKE): Is there a role for fibrinogen and electrocardiography?","volume":"56","author":"Moons","year":"2002"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib82","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S0140-6736(97)03079-1","article-title":"Chronic infections and coronary heart disease: is there a link?","volume":"350","author":"Danesh","year":"1997","journal-title":"Lancet"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib83","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1161\/01.CIR.103.15.1936","article-title":"Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis","volume":"103","author":"Newby","year":"2001","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib84","doi-asserted-by":"crossref","first-page":"e55175","DOI":"10.1371\/journal.pone.0055175","article-title":"Hemostatic factors and risk of coronary heart disease in general populations: new prospective study and updated meta-analyses","volume":"8","author":"Willeit","year":"2013","journal-title":"PLoS One"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib85","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0140-6736(87)93050-9","article-title":"Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction","volume":"2","author":"Hamsten","year":"1987","journal-title":"Lancet"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib86","first-page":"2030","article-title":"Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease","volume":"88","author":"Jansson","year":"1993","journal-title":"A 7-year follow-up. Circulation"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib87","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1161\/01.CIR.83.5.1685","article-title":"Evidence for reduced fibrinolytic activity in unstable angina at rest. Clinical, biochemical, and angiographic correlates","volume":"83","author":"Zalewski","year":"1991","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib88","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1161\/01.CIR.94.9.2057","article-title":"Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities","volume":"94","author":"Juhan-Vague","year":"1996","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib89","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJM198512193132501","article-title":"Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction","volume":"313","author":"Hamsten","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib90","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1161\/01.CIR.91.10.2520","article-title":"Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris","volume":"91","author":"Hoffmeister","year":"1995","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib91","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0735-1097(97)00531-7","article-title":"Endothelial tissue-type plasminogen activator release in coronary heart disease: transient reduction in endothelial fibrinolytic reserve in patients with unstable angina pectoris or acute myocardial infarction","volume":"31","author":"Hoffmeister","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib92","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1055\/s-0038-1648414","article-title":"A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis","volume":"67","author":"Huber","year":"1992","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib93","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1161\/01.ATV.14.11.1741","article-title":"Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke","volume":"14","author":"Margaglione","year":"1994","journal-title":"Arterioscler Thromb"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib94","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/0140-6736(93)92062-X","article-title":"Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study","volume":"342","author":"Meade","year":"1993","journal-title":"Lancet"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib95","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/0140-6736(93)90998-V","article-title":"Endogenous tissue-type plasminogen activator and risk of myocardial infarction","volume":"341","author":"Ridker","year":"1993","journal-title":"Lancet"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib96","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1055\/s-0037-1614231","article-title":"Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study","volume":"79","author":"Lowe","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib97","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1055\/s-0037-1615353","article-title":"Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction\u2014the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction","volume":"80","author":"Scarabin","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib98","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1055\/s-0037-1614340","article-title":"The 4G4G genotype of the plasminogen activator inhibitor 4G\/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease","volume":"82","author":"Gardemann","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib99","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/S0735-1097(99)00424-6","article-title":"Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction","volume":"34","author":"Anderson","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib100","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1161\/hc5001.100793","article-title":"Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review","volume":"104","author":"Boekholdt","year":"2001","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib101","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/01.CIR.101.1.67","article-title":"Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women","volume":"101","author":"Roest","year":"2000","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib102","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1161\/01.CIR.101.3.264","article-title":"Association of blood pressure with fibrinolytic potential in the Framingham offspring population","volume":"101","author":"Poli","year":"2000","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib103","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1001\/jama.283.2.221","article-title":"Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study","volume":"283","author":"Meigs","year":"2000","journal-title":"JAMA"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib104","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/0026-0495(94)90020-5","article-title":"Hyperinsulinemia predicts low tissue plasminogen activator activity in a healthy population: the Northern Sweden MONICA Study","volume":"43","author":"Eliasson","year":"1994","journal-title":"Metabolism"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib105","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/aje\/152.10.897","article-title":"Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome","volume":"152","author":"Sakkinen","year":"2000","journal-title":"Am J Epidemiol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib106","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3109\/07853899608999095","article-title":"Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus","volume":"28","author":"Juhan-Vague","year":"1996","journal-title":"Ann Med"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib107","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2337\/diab.43.1.104","article-title":"Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients","volume":"43","author":"McGill","year":"1994","journal-title":"Diabetes"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib108","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ecl.2004.03.008","article-title":"Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status","volume":"33","author":"Devaraj","year":"2004","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib109","doi-asserted-by":"crossref","first-page":"12412","DOI":"10.1016\/S0021-9258(18)42289-2","article-title":"Post-transcriptional regulation of expression of plasminogen activator inhibitor type 1 mRNA by insulin and insulin-like growth factor 1","volume":"267","author":"Fattal","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib110","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1161\/01.ATV.16.1.89","article-title":"Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL","volume":"16","author":"Sironi","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib111","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1161\/01.ATV.13.12.1822","article-title":"Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis","volume":"13","author":"Nordt","year":"1993","journal-title":"Arterioscler Thromb"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib112","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s001250050868","article-title":"Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals","volume":"41","author":"Eriksson","year":"1998","journal-title":"Diabetologia"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib113","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1161\/01.ATV.10.6.1067","article-title":"Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein","volume":"10","author":"Stiko-Rahm","year":"1990","journal-title":"Arteriosclerosis"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib114","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1161\/01.ATV.12.1.19","article-title":"Hypertriglyceridemia and regulation of fibrinolytic activity","volume":"12","author":"Mussoni","year":"1992","journal-title":"Arterioscler Thromb"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib115","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1161\/01.ATV.13.12.1865","article-title":"Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group","volume":"13","author":"Juhan-Vague","year":"1993","journal-title":"Arterioscler Thromb"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib116","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1161\/01.CIR.0000080884.27358.49","article-title":"Study of Health Assessment and Risk Evaluation in Aboriginal Peoples Investigators. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease","volume":"108","author":"Anand","year":"2003","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib117","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0021-9150(98)00144-0","article-title":"Effects of lipids and lipoproteins on thrombosis and rheology","volume":"140","author":"Rosenson","year":"1998","journal-title":"Atherosclerosis"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib118","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/01.ATV.14.3.438","article-title":"Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells","volume":"14","author":"Levin","year":"1994","journal-title":"Arterioscler Thromb"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib119","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/01.ATV.13.3.338","article-title":"Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs. An LDL receptor-independent phenomenon","volume":"13","author":"Tremoli","year":"1993","journal-title":"Arterioscler Thromb"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib120","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-0038-1648148","article-title":"Relationships of plasma viscosity, coagulation and fibrinolysis to coronary risk factors and angina","volume":"65","author":"Lowe","year":"1991","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib121","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0021-9150(90)90004-3","article-title":"Dietary regulation of fibrinolytic factors","volume":"84","author":"Mehrabian","year":"1990","journal-title":"Atherosclerosis"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib122","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1161\/01.ATV.16.3.381","article-title":"Plasminogen activator inhibitor-1, tissue-type plasminogen activator, and fibrinogen: effect of dieting with or without exercise in overweight postmenopausal women","volume":"16","author":"Svendsen","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib123","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0268-9499(08)80046-X","article-title":"Can physical activity explain the differences in insulin levels and fibrinolytic activity between young Indo-origin and European relative of patients with coronary heart disease","volume":"9","author":"Shaukat","year":"1995","journal-title":"Fibrinolysis"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib124","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/0049-3848(88)90119-3","article-title":"Increased blood fibrinolytic activity after physical exercise: comparative study in individuals with different sporting activities and in patients after myocardial infarction taking part in a rehabilitation sports program","volume":"51","author":"Speiser","year":"1988","journal-title":"Thromb Res"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib125","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0049-3848(89)90437-4","article-title":"Influence of a rehabilitation sports programme on the fibrinolytic activity of patients after myocardial infarction","volume":"55","author":"Estelles","year":"1989","journal-title":"Thromb Res"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib126","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1055\/s-0038-1647350","article-title":"Impact of smoking, physical training and weight reduction on FVII, PAI-1 and hemostatic markers in sedentary men","volume":"64","author":"Gris","year":"1990","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib127","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1055\/s-0037-1614339","article-title":"Regular exercise, plasminogen activator inhibitor-1 (PAI-1) activity and the 4G\/5G promoter polymorphism in the PAI-1 gene","volume":"82","author":"Vaisanen","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib128","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1161\/hc3701.096067","article-title":"Alcohol consumption and hemostatic factors: analysis of the Framingham Offspring cohort","volume":"104","author":"Mukamal","year":"2001","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib129","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1001\/jama.279.20.1643","article-title":"Antiatherothrombotic properties of statins: implications for cardiovascular event reduction","volume":"279","author":"Rosenson","year":"1998","journal-title":"JAMA"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib130","first-page":"270","article-title":"Changes induced by gemfibrozil on lipidic, coagulative and fibrinolytic pattern in patients with type IV hyperlipoproteinemia","volume":"7","author":"Avellone","year":"1988","journal-title":"Int Angiol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib131","first-page":"829","article-title":"Hypercoagulable state in patients with hypercholesterolemia: effects of pravastatin","volume":"14","author":"Wada","year":"1992","journal-title":"Clin Ther"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib132","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00001721-199509000-00007","article-title":"Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridemia","volume":"6","author":"Avellone","year":"1995","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib133","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/01.CIR.96.2.442","article-title":"Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators","volume":"96","author":"Vaughan","year":"1997","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib134","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1161\/hc0402.102929","article-title":"Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1","volume":"105","author":"Pahor","year":"2002","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib135","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/hc0302.102570","article-title":"Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women","volume":"105","author":"Brown","year":"2002","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib136","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1161\/01.CIR.99.23.2983","article-title":"Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure","volume":"99","author":"Goodfield","year":"1999","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib137","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1473-0502(01)00140-9","article-title":"Extracorporeal fibrinogen adsorption--efficacy, selectivity and safety in healthy subjects and patients with foot ulcers","volume":"26","author":"Richter","year":"2002","journal-title":"Transfus Apher Sci"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib138","first-page":"476","article-title":"The Writing Group for the Estradiol Clotting Factors Study","volume":"75","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib139","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2141.1998.00594.x","article-title":"Effects of hormone replacement therapies on fibrinogen and plasma viscosity in postmenopausal women","volume":"100","author":"Frohlich","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib140","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jama.279.18.1445","article-title":"Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women","volume":"279","author":"Walsh","year":"1998","journal-title":"JAMA"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib141","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/jama.288.1.49","article-title":"Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen\/progestin Replacement Study follow-up (HERS II)","volume":"288","author":"Grady","year":"2002","journal-title":"JAMA"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib142","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Writing Group for the Women\u05f3s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women\u05f3s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib143","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1056\/NEJM199309023291006","article-title":"Thrombolysis in acute myocardial infarction","volume":"329","author":"Anderson","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib144","doi-asserted-by":"crossref","first-page":"4670","DOI":"10.1073\/pnas.83.13.4670","article-title":"Autonomous functions of structural domains on human tissue-type plasminogen activator","volume":"83","author":"van Zonneveld","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib145","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1016\/S0021-9258(18)69021-0","article-title":"Structure-function analysis with tissue-type plasminogen activator. Effect of deletion of NH2-terminal domains on its biochemical and biological properties","volume":"263","author":"Kalyan","year":"1988","journal-title":"J Biol Chem"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib146","doi-asserted-by":"crossref","first-page":"10112","DOI":"10.1074\/jbc.275.14.10112","article-title":"Identification of the mechanism responsible for the increased fibrin specificity of TNK-tissue plasminogen activator relative to tissue plasminogen activator","volume":"275","author":"Stewart","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib147","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/01.RVI.0000202751.74625.79","article-title":"Tenecteplase in acute lower-leg ischemia: efficacy, dose, and adverse events","volume":"17","author":"Hull","year":"2006","journal-title":"J Vasc Interv Radiol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib148","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0741-5214(94)70078-8","article-title":"Thrombolysis with tissue-plasminogen activator: results with a high-dose transthrombus technique","volume":"19","author":"Ward","year":"1994","journal-title":"J Vasc Surg"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib149","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800840517","article-title":"Prospective randomized trial of high-dose bolus versus low-dose tissue plasminogen activator infusion in the management of acute limb ischaemia. Thrombolysis Study Group","volume":"84","author":"Braithwaite","year":"1997","journal-title":"Br J Surg"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib150","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1055\/s-0038-1648203","article-title":"A new intra arterial rt-PA dosage regimen in peripheral arterial occlusion: bolus followed by continuous infusion","volume":"65","author":"Juhan","year":"1991","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib151","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1148\/radiology.188.3.8351363","article-title":"Intraarterial thrombolysis of lower extremity occlusions: prospective, randomized comparison of forced periodic infusion and conventional slow continuous infusion","volume":"188","author":"Kandarpa","year":"1993","journal-title":"Radiology"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib152","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib153","series-title":"Rutherford\u2019s Vascular Surgery","article-title":"Acute deep venous thrombosis: pathophysiology and natural history","author":"Cronenwett","year":"2014"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib154","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1160\/TH09-01-0053","article-title":"OPTIMEV-SFMV Investigators. Comparative study on risk factors and early outcome of symptomatic distal versus proximal deep vein thrombosis: results from the OPTIMEV study","volume":"102","author":"Galanaud","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib155","first-page":"CD002783","article-title":"Thrombolysis for acute deep vein thrombosis","volume":"1","author":"Watson","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib156","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1053\/ejvs.2002.1665","article-title":"Early results of thrombolysis vs anticoagulation in iliofemoral venous thrombosis. A randomised clinical trial","volume":"24","author":"Elsharawy","year":"2002","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib157","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1148\/radiology.211.1.r99ap4739","article-title":"Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry","volume":"211","author":"Mewissen","year":"1999","journal-title":"Radiology"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib158","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1067\/mva.2000.105664","article-title":"Catheter-directed thrombolysis for iliofemoral deep venous thrombosis improves health-related quality of life","volume":"32","author":"Comerota","year":"2000","journal-title":"J Vasc Surg"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib159","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/j.1538-7836.2011.04298.x","article-title":"Recurrent venous thrombosis, post-thrombotic syndrome and quality of life after catheter-directed thrombolysis in severe proximal deep vein thrombosis","volume":"9","author":"Ghanima","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib160","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ejvs.2004.06.007","article-title":"Preservation of venous valve function after catheter-directed and systemic thrombolysis for deep venous thrombosis","volume":"28","author":"Laiho","year":"2004","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib161","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0002-9343(84)90656-9","article-title":"Pooled analyses of randomized trials of streptokinase and heparin in phlebographically documented acute deep venous thrombosis","volume":"76","author":"Goldhaber","year":"1984","journal-title":"Am J Med"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib162","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0002-9343(90)90494-X","article-title":"Streptokinase therapy for deep vein thrombosis: a comprehensive review of the English literature","volume":"88","author":"Rogers","year":"1990","journal-title":"Am J Med"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib163","first-page":"172S","article-title":"Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Results of a randomized trial","volume":"97","author":"Turpie","year":"1990","journal-title":"Chest"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib164","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0002-9149(97)00315-9","article-title":"Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism","volume":"80","author":"Daniels","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib165","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/archinte.1992.00400180117019","article-title":"The potential role of thrombolytic therapy in venous thrombosis","volume":"152","author":"Markel","year":"1992","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib166","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/archinte.163.14.1711","article-title":"Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data","volume":"163","author":"Horlander","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib167","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1001\/jama.1986.03370150081032","article-title":"Pulmonary embolism as a cause of death. The changing mortality in hospitalized patients","volume":"255","author":"Dismuke","year":"1986","journal-title":"JAMA"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib168","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0033-0620(75)80017-X","article-title":"Natural history of pulmonary embolism","volume":"17","author":"Dalen","year":"1975","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib169","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/archinte.1991.00400050081016","article-title":"A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study","volume":"151","author":"Anderson","year":"1991","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib170","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1056\/NEJMra072753","article-title":"Acute pulmonary embolism","volume":"358","author":"Tapson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib171","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S0140-6736(98)07534-5","article-title":"Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER)","volume":"353","author":"Goldhaber","year":"1999","journal-title":"Lancet"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib172","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1161\/01.CIR.0000137826.09715.9C","article-title":"Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials","volume":"110","author":"Wan","year":"2004","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib173","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2014.5990","article-title":"Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis","volume":"311","author":"Chatterjee","year":"2014","journal-title":"JAMA"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib174","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.amjmed.2011.10.015","article-title":"Thrombolytic therapy in unstable patients with acute pulmonary embolism: saves lives but underused","volume":"125","author":"Stein","year":"2012","journal-title":"Am J Med"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib175","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.amjcard.2012.09.027","article-title":"MOPETT Investigators. Moderate pulmonary embolism treated with thrombolysis (from the \"MOPETT\" trial)","volume":"111","author":"Sharifi","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib176","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0002-9149(98)00513-X","article-title":"Comparison of alteplase versus heparin for resolution of major pulmonary embolism","volume":"82","author":"Konstantinides","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib177","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJM198010093031502","article-title":"Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism","volume":"303","author":"Sharma","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib178","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1161\/CIRCULATIONAHA.113.005544","article-title":"Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism","volume":"129","author":"Kucher","year":"2014","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib179","doi-asserted-by":"crossref","unstructured":"Wang C, Zhai Z, China Venous Thromboembolism (VTE) Study Group et al. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest 2010;137(2):254-62. doi: 10.1378\/chest.09-0765. Epub 2009 Sep 9","DOI":"10.1378\/chest.09-0765"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib180","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1378\/chest.98.6.1473","article-title":"A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism","volume":"98","author":"Levine","year":"1990","journal-title":"Chest"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib181","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jvs.2010.08.064","article-title":"Endovascular therapy for acute limb ischemia","volume":"53","author":"Kashyap","year":"2011","journal-title":"J Vasc Surg"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib182","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.avsg.2011.05.017","article-title":"Endovascular management of acute limb ischemia","volume":"26","author":"Hynes","year":"2012","journal-title":"Ann Vasc Surg"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib183","doi-asserted-by":"crossref","unstructured":"Ouriel K, Veith FJ, Sasahara AA. Thrombolysis or peripheral arterial surgery: phase I results. TOPAS Investigators. J Vasc Surg 1996;23:64, 73; discussion 74\u221275.","DOI":"10.1016\/S0741-5214(05)80036-9"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib184","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00000658-199409000-00003","article-title":"Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE trial","volume":"220","year":"1994","journal-title":"Ann Surg"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib185","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0741-5214(96)70067-8","article-title":"Surgical revascularization versus thrombolysis for nonembolic lower extremity native artery occlusions: results of a prospective randomized trial. The STILE Investigators. Surgery versus Thrombolysis for Ischemia of the Lower Extremity","volume":"24","author":"Weaver","year":"1996","journal-title":"J Vasc Surg"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib186","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1177\/152660280100800618","article-title":"Study on Local Thrombolysis. Recombinant tissue plasminogen activator versus urokinase for local thrombolysis of femoropopliteal occlusions: a prospective, randomized multicenter trial","volume":"8","author":"Mahler","year":"2001","journal-title":"J Endovasc Ther"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib187","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1148\/radiology.175.1.2107563","article-title":"Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial and graft occlusions: a randomized trial","volume":"175","author":"Meyerovitz","year":"1990","journal-title":"Radiology"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib188","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0720-048X(96)00742-5","article-title":"Comparison of tissue plasminogen activator and urokinase in the local infiltration thrombolysis of peripheral arterial occlusions","volume":"22","author":"Schweizer","year":"1996","journal-title":"Eur J Radiol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib189","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/01.RVI.0000112621.22203.12","article-title":"Catheter-directed thrombolytic therapy for limb ischemia: current status and controversies","volume":"15","author":"Razavi","year":"2004","journal-title":"J Vasc Interv Radiol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib190","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S1051-0443(07)61949-6","article-title":"Declining-dose study of reteplase treatment for lower extremity arterial occlusions","volume":"13","author":"Castaneda","year":"2002","journal-title":"J Vasc Interv Radiol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib191","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/1538574413497107","article-title":"Fibrinogen level as a surrogate for the outcome of thrombolytic therapy using tissue plasminogen activator for acute lower extremity intravascular thrombosis","volume":"47","author":"Skeik","year":"2013","journal-title":"Vasc Endovascular Surg"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib192","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s00270-011-0258-z","article-title":"Quality improvement guidelines for percutaneous catheter-directed intra-arterial thrombolysis and mechanical thrombectomy for acute lower-limb ischemia","volume":"34","author":"Karnabatidis","year":"2011","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib193","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1161\/01.CIR.92.7.1883","article-title":"Superficial accumulation of plasminogen during plasma clot lysis","volume":"92","author":"Sakharov","year":"1995","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2015.04.003_bib194","doi-asserted-by":"crossref","first-page":"22228","DOI":"10.1016\/S0021-9258(18)45694-3","article-title":"The role of fragment X polymers in the fibrin enhancement of tissue plasminogen activator-catalyzed plasmin formation","volume":"265","author":"Suenson","year":"1995","journal-title":"J Biol Chem"}],"container-title":["Seminars in Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895796715000320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895796715000320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T14:29:38Z","timestamp":1651674578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0895796715000320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":194,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0895796715000320"],"URL":"https:\/\/doi.org\/10.1053\/j.semvascsurg.2015.04.003","relation":{},"ISSN":["0895-7967"],"issn-type":[{"value":"0895-7967","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fibrinogen and catheter-directed thrombolysis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Vascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semvascsurg.2015.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}